BMY Has CRASHED To A NEW 52 Week Low! | MASSIVE Upside! | Bristol-Myers Squibb (BMY) Stock Analysis
ฝัง
- เผยแพร่เมื่อ 17 พ.ค. 2024
- Stock Valuation Model: www.buymeacoffee.com/dividend...
️Feel free to buy me a coffee: www.buymeacoffee.com/DIVIDEND...
Join the FREE weekly Newsletter: DividendTalks.substack.com/subscribe
Join the community in our Discord: / dividendtalks
Follow me on X: www.x.com/DividendTalks
Free shares up to £100 by joining Trading212:
www.trading212.com/invite/Gux...
20% OFF Seeking Alpha Premium: www.sahg6dtr.com/29N4DP9/R74QP/
In this video we will analyse Bristol-Myers Squibb (BMY) stock using our 4 valuations methods to get to our intrinsic value. We will then apply a margin of safety to get to our acceptable buy price.
We will also take a look at the dividend safety and other key financial metrics. Let me know your thoughts in the comments.
I am not a financial advisor or licensed professional. Nothing I say or produce on TH-cam or anywhere else, should be considered as advice. All content is for educational purposes only. I am not responsible for any financial losses or gains. Invest and trade at your own risk.
🧮 Stock Valuation Model: www.buymeacoffee.com/dividendtalks/extras
☕️ Feel free to buy me a coffee: www.buymeacoffee.com/DIVIDENDTALKS
📰 Join the FREE weekly Newsletter: DividendTalks.substack.com/subscribe
💬 Join the community in our Discord: www.patreon.com/DividendTalks
👋 Follow me on X: www.x.com/DividendTalks
💰 Free shares up to £100 by joining Trading212:
www.trading212.com/invite/Gux0x99S
20% OFF Seeking Alpha Premium:
www.sahg6dtr.com/29N4DP9/R74QP
A
I loaded up on BMY. The stock is very cheap and if you take away the last quarter when they took a one time massive charge for the acquisition of Karuna, the forward P/E ratio is 5.8, with single digit growing earnings. The patent expiration is overblown at the moment, as their key patents only expire in 2028. BMY has a price/revenue ratio of 1.88, solid dividend of 5.8%, strong net cash flow from operations ($13.8Bn in the last 4 quarters from $45Bn in revenue), and not a crazy amount of debt ($55.7Bn) that they plan to reduce by $10Bn in the next 2 years.
I hope the stock stays low/lower for a few more months to buy more of it. At low $40s/share it's a fantastic value in my book. Oh yeah... if we're going into a recession and the Fed starts cutting rates, BMY looks even better.
Great analysis.
So, if all this is good news, Why do investors keep selling it?
@@annasad For every seller there's a buyer. So there are people happy to buy BMY at these discounted prices. Wait until BMY has P/E ratio of under 6, positive revenue, over 6% dividend in a recession with 0% interest rates. I did not buy the stock for a quick buck. My horizon is 12-18mo.
Hit my buy price today!
Thanks for covering BMY! I thought it was a steal at $49 when I began my position, but I hope it stays this low so I can build up a larger position in the meantime.
You are very welcome 😊
I may be cheap right now but they are facing expirations of their top revenue medications and could see up to a 70% cut in their revenue. They have til then to find new products to market and make up for those losses also by doing so they are adding on more debt. This would be a very speculative bet to make and not sure if its worth the risk at the currentl valuation.
I agree, but at some point the low price removes risk. A 50% drop in earnings still puts them at a ~13 P/E.
I will be adding to my BM portfolio.
Adding this to my potentials list. Thanks!
You’re very welcome 😊
technically speaking: BMY is testing a long term monthly support around 40.00$
great video
Thank you, appreciate the kind words 😊
Sold it six weeks ago.
I own this in a portfolio. DCA into it. Either going to sell for ABBV or keep it and buy some more. It's momentum and potential growth are what worries me. The major hit has been taken.
I've been holding a full position in BMY for several years and it's down an irritating amount. I've been considering selling, taking the loss, and moving on to better companies, but I haven't executed on that yet. I'm reinvesting dividends but otherwise not buying more shares. I'd like to see management prove they can be profitable before investing more.
I am in the same situation as you are. I held a normal size of position and did think taking a loss and move on. But, I recalled the Celgene acquisition has transferred the company into a big biotech/pharma firm with a stable revenue generation and a strong product pipeline. I never expect the new CEO Chris Boerner continue with expensive shopping spree spending $14B betting on one product with no revenue. It messed up its finance and the Market responded so negatively beyond my imagination.
@@leonardshiang1049 Yup, they need to stop doing this and strengthen their balance sheet. Enough with acquisitions. Prove that you can innovate in house and that the recent acquisitions work.
Bmy is a div stock. Not a growth stock. Lol. I am backing up my truck to buy the heck out of this high yielder right now.
I always laugh when people divide stocks, or companies, into growth, dividend, value, etc. The only thing that really matters is total return. Whether your money comes from dividends or share price appreciation, it makes little difference. I'd like to see gains in both areas, of course, but when the share price is down 40%, getting nice dividends does not balance the equation. I wonder if people would be so eager to buy at $70 per share, where the yield would be far less. If the answer is no, then you understand how I feel about it.
@@SwingTradeTipsForAll Total growth is irrelevant in div growth portfolios. The stock never gets sold. Ever. Just gets passed down gen to gen.
I really hate when a stock plunges for no good reason, BMY is a perfect example.
No offense, but are you an investor? That's the very definition of when Buffet says a stock is on sale...
@@Daniel-ld3zi My main frustration with BMY is that it hasn't started going back up yet, if it had dropped then started rebounding steadily over a few months then that makes sense.
Thanks a lot for this update 👍
You’re always welcome! 😊
Thanks for analyzing (BMY) it’s been in my watchlist for few years my entry price on (BMY) is $33
Lol😂
It will never drop that far
unlikely
I'm building up a position by adding shares for about 3 months and still going on.
Waiting for it to hit $40 before I am interested.
Would you do analysis on GILD?
I literally did in my latest video today 😅
I DCA!.
BMY is the classic zombie company
DCA’ing weekly
Low 41,07 uds .
BMY has become one of the most hated companies in S&P 500. The new CEO is just incompetent and has messed up the company's finance.
And he is treated likewise by investors.
First
Thanks for the support! 😊
🤓🤓🤓
Crashed 8 % more from the time you shoot the video. The challenge is, that there is no Floor for such Stocks
still crashing as of now....
L